If a supplied lot fails agreed specifications, we’ll replace it at no cost or refund its purchase price in full.
Quality test failed? Free replacement or full refund.
Off-spec? Free replacement or full refund.
PCAC will review 7 peptides for the 503A bulks list, BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, Epithalon. Read our briefing →
PCAC will review 7 peptides for the 503A bulks list. Read →
FDA PCAC reviews 7 peptides in July. Read →
Reference-name product · composition documented per batch
Overview
Klow is a reference-name product appearing in upstream price tables under a commercial brand designation rather than a publicly defined chemical name. It is supplied as a single 80 mg combination fill, positioning Klow for bulk-distributor workflows. As with Adamax, PROSTAMAX, and the other reference-name SKUs in the catalog, the actual API identity, peptide sequence, and CAS designation is verified against the batch-specific COA before any order placement. PeptideXpo lists Klow to support distributor partners whose upstream price tables reference these commercial brands. The 80 mg combination fill in particular suggests bulk-distributor workflows. Direct end-buyers should request the verified composition disclosure from the regulatory team before placing an order, and the batch COA's component-level analysis is the operative document for any downstream regulatory or quality work.
Who buys this, and why
Custom-blend buyers are almost always OEM clients building a branded product around a specific ratio of two or more peptides. The development workflow is collaborative: ratio target, analytical method to verify it, stability protocol in the chosen carrier, and packaging selection are all defined in the OEM brief before the first commercial run. Sample-stage volumes are usually 5-10 g of finished blend; commercial MOQ depends on the components.
Primary buyer fit: regional distributors and re-sellers.
Specifications
Documentation available on request
Each picture is a low-resolution preview of a report's first page, with batch and report numbers covered. For the full, clear report, ask our sales team, naming the product and strength.
Batch COAKLOW (BPC+GHK-Cu+TB+KPV) 80 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Independent test fails? Full refund. How it works
Regulatory note
Reference-name product without publicly disclosed API identity; composition is documented on the batch-specific COA before any downstream regulatory or research use.
Frequently asked questions
The 80 mg figure is the combined per-vial quantity of the four-component blend, BPC-157, GHK-Cu, TB-500, and KPV co-filled in one vial, rather than 80 mg of a single API. The single large-format fill targets bulk-distributor workflows that benefit from larger per-vial quantities for downstream fractionation or for direct use in higher-dose preparation contexts. As with all reference-name SKUs, the component identities and per-component quantities are verified against the batch-specific COA at receipt; the fill format is independent of that identity confirmation. For buyers needing the largest possible per-vial quantity, the 80 mg Klow fill is among the larger formats in the reference-name SKU family.
Fractionating an 80 mg lyophilized bulk vial into smaller dispensing units requires controlled sterile-fill capability: reconstitution of the bulk lyophilizate in sterile diluent, sterile-filtration of the reconstituted solution, aliquot fill into smaller vials under ISO 7/8 cleanroom conditions, and terminal re-lyophilization in the smaller vials. Buyers without in-house sterile-fill infrastructure should use PeptideXpo's pre-fractionation OEM service rather than attempting in-house fractionation, the service splits the 80 mg batch into buyer-specified smaller fills (typically 5 mg, 10 mg, or 20 mg per smaller vial) under validated cleanroom conditions. The OEM-service approach is operationally simpler and the per-vial-output documentation chain is cleaner than the in-house path.
First-time Klow orders follow the standard 14-21 day production schedule from confirmed PO. Repeat orders against an established synthesis route compress to 10-14 days. The 80 mg fill in particular benefits from recurring-order economics, bulk production at this fill size is most cost-efficient when scheduled against a quarterly or semi-annual procurement cycle rather than ad-hoc single orders. Distributor partners with regular Klow procurement should discuss the schedule at quote stage; PeptideXpo can hold released-batch inventory against forecast orders for the largest-volume distributors, further compressing effective lead time.
Send any vial from your order to an independent laboratory of your choice. If the report shows the product does not meet the specification on its COA — purity below the stated minimum, or an identity that does not match — share the report with our sales team and we refund that product in full.
